Huapont Life Sciences Co., Ltd. is a China-based biotechnology and pharmaceutical company specializing in the research, development, production, and sales of pharmaceutical preparations and intermediates. Its core product portfolio includes medicines for dermatology, tuberculosis, anti-infection, respiratory diseases, anti-tumor treatments, and ophthalmology, along with health management products. Additionally, the company provides pesticide technical products, intermediates, and preparations, as well as GLP registration technical services. It operates in the pharmaceutical, agrochemical, new materials, and tourism sectors, serving both domestic and international markets. Founded in 1992 and headquartered in Chongqing, China, Huapont has expanded its operations through strategic acquisitions, including a 2023 acquisition of a smaller biotech firm for approximately $50 million to enhance its product line and increase market capabilities. The company is focused on growing its healthcare business, which now represents its main strategic priority, supported by recent partnerships with research institutions targeting innovative drug development and regulatory compliance for international market expansion. Huapont continues to develop new pharmaceuticals for chronic diseases, has improved operational efficiencies, and participates actively in global pharmaceutical development events. Its former agrochemical subsidiary Beijing Nutrichem was listed independently, emphasizing Huapont's shift toward healthcare and biopharmaceutical growth. The company also engages in advancing nano-antibody drug research through joint ventures and invests heavily in research and development with a long-term commitment to expanding its healthcare product offerings and market presence.